Literatur
-
1
ALLHAT Officers and Coordinators for ALLHAT .
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
JAMA.
2002;
288
2981-2997
-
2
Bloom. et al .
Compliance.
Clin Ther.
1998;
20
671-681
-
3
Der Spiegel .
Milliarden-Verschwendung mit Hochdruck-Medikamenten.
DER SPIEGEL.
2003;
14
, www.spiegel.de/spiegel/vorab/
-
4
Franse L V, Pahor M, Di Bari M, Somes G W, Cushman W C, Applegate W B.
Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program.
Hypertension.
2000;
35
1025-1030
-
5
2003 European Society of Hypertension .
European Society of Cardiology guidelines for the management of arterial hypertension. Guidelines Committee.
J Hypertension.
2003;
21
1011-1053
-
6
Lauterbach K W, Plamper E.
Effizienz in Zeiten knapper Arzneimittelbudgets.
Dtsch Ärzteblatt.
2003;
100
C1558-C1559
-
7
Prospective Studies Collaboration .
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.
Lancet.
2002;
360
1903-1913
-
8
Suter P M, Vetter W.
Metabolic effects of antihypertensive drugs.
J Hypertension (Suppl).
1995;
13
S11-17
-
9
Weber M A.
The ALLHAT Report: A Case of Information and Misinformation.
J Clin Hypertension.
2003;
V
9-13
Prof. Dr. Tomas Unger
Center for Cardiovascular Research (CCR), Institut für Pharmakologie und Toxikologie
Hessische Str. 3-4
10115 Berlin
